Insider Selling: uniQure (NASDAQ:QURE) Insider Sells $1,127,700.00 in Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the transaction, the insider directly owned 169,669 shares in the company, valued at approximately $4,251,905.14. This represents a 20.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

• On Wednesday, March 4th, Walid Abi-Saab sold 808 shares of uniQure stock. The stock was sold at an average price of $9.06, for a total transaction of $7,320.48.

uniQure Trading Down 4.9%

NASDAQ:QURE opened at $27.75 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.75 billion, a PE ratio of -7.97 and a beta of 0.87. The firm’s 50 day moving average is $17.95 and its 200 day moving average is $23.57. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Sell-side analysts expect that uniQure N.V. will post -3.68 earnings per share for the current year.

Institutional Trading of uniQure

Several institutional investors have recently added to or reduced their stakes in QURE. State Street Corp boosted its position in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after buying an additional 1,787,033 shares during the period. JPMorgan Chase & Co. boosted its position in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC boosted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the period. MPM Bioimpact LLC purchased a new stake in uniQure during the fourth quarter valued at about $33,062,000. Finally, Fred Alger Management LLC purchased a new stake in uniQure during the third quarter valued at about $75,320,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on QURE shares. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Barclays lowered their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Chardan Capital lifted their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Wolfe Research started coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.